How Should We Approach Locally Advanced Squamous Cell Carcinoma of Head and Neck Cancer Patients Ineligible for Standard Non-surgical Treatment?
Sign Up to like & getrecommendations! Published in 2020 at "Current Oncology Reports"
DOI: 10.1007/s11912-020-00984-x
Abstract: Cisplatin has been established as one of the most important agents in multidisciplinary treatment for head and neck cancer (HNC). However, since HNC patients are often elderly and typically have several comorbidities, a limited number… read more here.
Keywords: hnc; dose cisplatin; treatment; patients ineligible ... See more keywords
Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Therapeutic Advances in Hematology"
DOI: 10.1177/2040620719882822
Abstract: Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a globally poor outcome, especially in patients ineligible for intensive chemotherapy. Until recently, therapeutic options for these patients included low-dose cytarabine (LDAC) or the hypomethylating… read more here.
Keywords: venetoclax; ineligible intensive; patients ineligible; intensive chemotherapy ... See more keywords
Predictors of the Overall Survival with Azacitidine Monotherapy in Untreated Acute Myeloid Leukemia Patients Ineligible for Intensive Therapy
Sign Up to like & getrecommendations! Published in 2022 at "Internal Medicine"
DOI: 10.2169/internalmedicine.0264-22
Abstract: Objective The prognostic factors for azacitidine in untreated acute myeloid leukemia (AML) patients ineligible for intensive therapy remain unknown. To identify prognostic factors for azacitidine monotherapy and assist clinicians in deciding whether to use azacitidine… read more here.
Keywords: intensive therapy; ineligible intensive; azacitidine monotherapy; patients ineligible ... See more keywords